Johnson & Johnson Pre-Paid Expenses 2012-2026 | JNJ
Johnson & Johnson pre-paid expenses from 2012 to 2026. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
- Johnson & Johnson pre-paid expenses for the quarter ending March 31, 2026 were $4.153B, a 1.66% increase year-over-year.
- Johnson & Johnson pre-paid expenses for 2025 were $4.153B, a 1.66% increase from 2024.
- Johnson & Johnson pre-paid expenses for 2024 were $4.085B, a 9.5% decline from 2023.
- Johnson & Johnson pre-paid expenses for 2023 were $4.514B, a 56.95% increase from 2022.
|
Johnson & Johnson Annual Pre-Paid Expenses (Millions of US $) |
|
|---|---|
| 2025 | $4,153 |
| 2024 | $4,085 |
| 2023 | $4,514 |
| 2022 | $2,876 |
| 2021 | $3,701 |
| 2020 | $3,132 |
| 2019 | $2,392 |
| 2018 | $2,699 |
| 2017 | $2,537 |
| 2016 | $3,282 |
| 2015 | $3,047 |
| 2014 | $3,486 |
| 2013 | $4,003 |
| 2012 | $3,084 |
| 2011 | $2,633 |
|
Johnson & Johnson Quarterly Pre-Paid Expenses (Millions of US $) |
|
|---|---|
| 2025-12-31 | $4,153 |
| 2025-09-30 | $4,292 |
| 2025-06-30 | $4,360 |
| 2025-03-31 | $4,091 |
| 2024-12-31 | $4,085 |
| 2024-09-30 | $4,175 |
| 2024-06-30 | $4,379 |
| 2024-03-31 | $4,455 |
| 2023-12-31 | $4,514 |
| 2023-09-30 | $4,196 |
| 2023-06-30 | $2,397 |
| 2023-03-31 | $2,921 |
| 2022-12-31 | $2,876 |
| 2022-09-30 | $3,592 |
| 2022-06-30 | $3,703 |
| 2022-03-31 | $3,452 |
| 2021-12-31 | $3,701 |
| 2021-09-30 | $3,590 |
| 2021-06-30 | $3,492 |
| 2021-03-31 | $3,024 |
| 2020-12-31 | $3,132 |
| 2020-09-30 | $2,528 |
| 2020-06-30 | $2,588 |
| 2020-03-31 | $2,358 |
| 2019-12-31 | $2,392 |
| 2019-09-30 | $2,220 |
| 2019-06-30 | $2,411 |
| 2019-03-31 | $2,599 |
| 2018-12-31 | $2,699 |
| 2018-09-30 | $2,896 |
| 2018-06-30 | $2,569 |
| 2018-03-31 | $2,641 |
| 2017-12-31 | $2,537 |
| 2017-09-30 | $2,922 |
| 2017-06-30 | $2,954 |
| 2017-03-31 | $2,826 |
| 2016-12-31 | $3,282 |
| 2016-09-30 | $2,600 |
| 2016-06-30 | $3,122 |
| 2016-03-31 | $3,307 |
| 2015-12-31 | $3,047 |
| 2015-09-30 | $3,010 |
| 2015-06-30 | $3,058 |
| 2015-03-31 | $3,731 |
| 2014-12-31 | $3,486 |
| 2014-09-30 | $3,107 |
| 2014-06-30 | $3,982 |
| 2014-03-31 | $3,932 |
| 2013-12-31 | $4,003 |
| 2013-09-30 | $3,312 |
| 2013-06-30 | $3,425 |
| 2013-03-31 | $3,260 |
| 2012-12-31 | $3,084 |
| 2012-09-30 | $2,789 |
| 2012-06-30 | $2,894 |
| 2012-03-31 | $2,683 |
| 2011-12-31 | $2,633 |
| 2011-09-30 | $3,056 |
| 2011-06-30 | $3,290 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |